

MITOS OU REALIDADES NA PREVENÇÃO CARDIOVASCULAR


SUPLEMENTOS NA SAÚDE E DOENÇA CARDIOVASCULAR

Bruno Miranda Castilho

Cardiologia – Hospital Distrital de Santarém




Supplements for the Primary Prevention of Cardiovascular Disease and Cancer





THE PROBLEM



Dietary supplementation is a very common practice in developed countries

- Half of U.S. adults (52%) take one or more dietary supplements.
- Most commonly multivitamin supplements.





Articl

Dietary Supplement Use Differs by Socioeconomic and Health-Related Characteristics among U.S. Adults, NHANES 2011–2014

Alexandra E. Cowan 1, Shinyoung Jun 10, Jaime J. Gahche 2, Janet A. Tooze 3,


- Common reasons appointed for using dietary supplements:
 - Overall health and wellness.
 - Disease prevention, in particular cardiovascular disease and cancer.
 - Lose weight, have more energy.



Why US Adults Use Dietary Supplements


Regan L. Bailey, PhD, RD; Jaime J. Gahche, MPH; Paige E. Miller, PhD, RD; et al





- Dietary supplements are intensively advertised in the media.
 - Sales of nearly 50 billion dollars annually in the United States
 - Frequently use expressions such as "treat" and "prevent", some advertisements use the authority of medical profession
 - Many users feel so strongly about the potential health benefits that they <u>reported that they would</u>
 <u>continue to take dietary supplements even if they were shown to be ineffective</u> in regulated scientific studies
 - Dietary supplements like multivitamins are generally regulated as food products rather than pharmaceuticals





Knowledge of dietary supplements is not a core competency for medical education and is often overlooked.

- Practicing physicians lack knowledge in these areas and rarely investigate supplements that they
 may not be familiar with
- Frequent sources of physician's information about dietary supplements were advertisements

Medical Residents' Knowledge of Dietary Supplements

Authors: Bims H. Almar, MD, MSA, Tauha N. Rico, MHS, Sleghen D. Sisson, MD




JAMA | US Preventive Services Task Force | RECOMMENDATION STATEMENT

Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force



Supplements for the Primary Prevention of Cardiovascular Disease and Cancer







Most common dietary supplement taken in the U.S., with more than one-third of adults

reporting regular multivitamin use.

OBJECTIVE

• Prevent nutritional deficiency.

RATIONAL FOR MV use:

• The combination of essential vitamins and minerals contained in multivitamins may mirror healthier dietary patterns such as fruit and vegetable intake, which have been modestly and inversely associated with cancer and CVD risk in some studies





Key question 1:

What is the efficacy of multivitamin supplementation for reducing cardiovascular disease, cancer, and mortality in the general adult population?





MULTIVITAMINS


Is multivitamin supplementation effective?



Multivitamins in the Prevention of Cancer in Men

The Physicians' Health Study II Randomized Controlled Trial

J. Michael Gaziano, MD, MPH; Howard D. Sesso, ScD, MPH; William G. Christen, ScD; et al




No effect on cancer mortality or site-specific cancers





Largest randomized trial regarding multivitamins and cocoa extract.









Largest randomized trial regarding multivitamins and cocoa extract

Mean Follow up 3,6 years



No benefit on cancer mortality

No reduction of CV events

No reduction of all cause mortality

Daily MV supplementation was benefitial on cognition (P=0,007)



MULTIVITAMINS

Pooled analisys of 4 RCTs ~37.000 participants

No association between multivitamin use and cardiovascular disease mortality.

Key question 2:

What are the harms of multivitamin supplementation in the general adult population?

Harms of multivitamin use were reported in 9 RCTs (n = 51614)

Very few adverse effects

Slight increase in RASH (OR 1.01-1.12)





JAMA | US Preventive Services Task Force | RECOMMENDATION STATEMENT

Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force




 The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation with multivitamins for the prevention of cardiovascular disease or cancer.

The largest randomized trial (COSMOS) as only a follow up of \sim 3.5 years Small observational studies that suggest benefit



Supplements for the Primary Prevention of Cardiovascular Disease and Cancer









VITAMIN D

Approximately 20% of healthy adults in the UK take a supplement containing vitamin D.










Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

JoAnn E. Manson, M.D., Dr.P.H., Nancy R. Cook, Sc.D., I-Min Lee, M.B., B.S., Sc.D., William Christen, Sc.D., Shari S. Bassuk, Sc.D., Samia Mora, M.D., M.H.S., Heike Gibson, Ph.D., David Gordon, M.A.T., Trisha Copeland, M.S., R.D., Denise D'Agostino, B.S., Georgina Friedenberg, M.P.H., Claire Ridge, M.P.H., et al., for the VITAL Research Group[®]

- ~25.000 patients > 50 years old
- Primary end points were invasive cancer of any type and major cardiovascular events.



Supplementation with vitamin D <u>did</u> <u>not</u> result in a <u>lower</u> incidence of <u>invasive cancer</u> or <u>cardiovascular</u> <u>events</u> than placebo.

No excess risks of hypercalcemia or other adverse events were identified.



VITAMIN D





JAMA | US Preventive Services Task Force | RECOMMENDATION STATEMENT

Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force

Outcome	No. of studies	No. analyzed	% with event		Odds ratio	Favors : Favors	
			Intervention	Control	(95% CI)	intervention control	
Vitamin D							
All-cause mortality	27	117082	5	5.7	0.96 (0.91-1.02)	Ė	
CVD events	7	74925	8.1	8.2	1.00 (0.95-1.05)	ė.	
Any cancer	19	86899	6.7	6.8	0.98 (0.92-1.03)		


No benefit in preventing cancer

No benefit in CV events

No benefit in all cause mortality








The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation with single or paired nutrients (other than beta carotene and vitamin E) for the prevention of cardiovascular disease or cancer.

- It is unclear whether the effect of vitamin D on health outcomes might vary based on patient population characteristics (eg, baseline vitamin D level or diet quality).
- Follow-up may be too short to detect an effect on cancer-specific mortality.



Supplements for the Primary Prevention of Cardiovascular Disease and Cancer










Long-Term Follow-Up for Mortality and Cancer in a Randomized Placebo-Controlled Trial of Vitamin D₃ and/or Calcium (RECORD Trial)

Alison Avenell, Graeme S. MacLennan, David J. Jenkinson, Gladys C. McPherson,


~5000 healthy individual

Randomized to calcium, vitamin D + calcium, vitamin D or placebo











JAMA | US Preventive Services Task Force | RECOMMENDATION STATEMENT

Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer

 $US\ Preventive\ Services\ Task\ Force\ Recommendation\ Statement$

US Preventive Services Task Force

Outcome	No. of studies	No. analyzed	% with event		Odds ratio	Favors : Favors	
			Intervention	Control	(95% CI)	intervention c	control
Calcium							
All-cause mortality	6	8394	13.1	12.7	1.05 (0.92-1.21)	I	-
CVD events	4	4076	10.7	9.7	1.11 (0.90-1.36)		-
Any cancer ^a	3	5051	8.7	8.9	0.94 (0.41-2.14)	-	

No benefit in preventing cancer

No benefit in CV events

No benefit in all cause mortality



HARMS IN SUPPLEMENTATION



Are there serious harms in supplementation?





RESEARCH

Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials

Rational: Vitamin E antioxidant

properties might protect

against cardiovascular disease.





Fig 3 | Relative risks of the effect of vitamin E on haemorrhagic stroke for individual trials and for the pooled population

Increases Hemorragic stroke in 22%

Decreases risk of ischemic stroke in 10%



HARMS IN SUPPLEMENTATION



Are there serious harms in supplementation?







ORIGINAL ARTICLE

The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers

~30.000 male smokers healthy individual

Randomized to Vitamin E, Beta Carotene or placebo





Significant increase of lung cancer with beta carotene supplementation

No benefit with vitamin E



Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer

Updated Evidence Report and Systematic Review for the US Preventive Services Task Force



	No. of studies	No. analyzed	% with event		Odds ratio	Favors : Favors
Outcome			Intervention	Control	(95% CI)	intervention control
Beta carotene						
All-cause mortality	6	112820	5.4	5.1	1.06 (1.00-1.12)	=
CVD mortality	5	94506	2.8	2.6	1.10 (1.02-1.19)	=
CVD events	2	61947	3.5	3.5	1.01 (0.92-1.10)	ė.
Any cancer	2	61947	5.3	5.4	0.99 (0.92-1.07)	ė.
Lung cancer ^c	4	94830	1.2	1	1.20 (1.01-1.42)	■-
Vitamin A						
All-cause mortality ^d	1	2297	5.4	4.6	1.16 (0.80-1.69)	
Beta carotene or vitamin A						
All-cause mortality	7	115 117	5.4	5.1	1.06 (1.01-1.12)	—
Vitamin E						
All-cause mortality	9	107772	6.9	6.8	1.02 (0.97-1.07)	
CVD events	4	62136	5.1	5.2	0.96 (0.90-1.04)	p
Any cancer	5	76777	8.8	8.6	1.02 (0.98-1.08)	
Vitamin D						
All-cause mortality	27	117 082	5	5.7	0.96 (0.91-1.02)	Ė
CVD events	7	74925	8.1	8.2	1.00 (0.95-1.05)	=
Any cancer	19	86899	6.7	6.8	0.98 (0.92-1.03)	
Calcium						
All-cause mortality	6	8394	13.1	12.7	1.05 (0.92-1.21)	•
CVD events	4	4076	10.7	9.7	1.11 (0.90-1.36)	-
Any cancer ^a	3	5051	8.7	8.9	0.94 (0.41-2.14)	-





JAMA | US Preventive Services Task Force | RECOMMENDATION STATEMENT

Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer US Preventive Services Task Force Recommendation Statement


US Preventive Services Task Force

USPSTF assessment

- The USPSTF concludes with moderate certainty that the harms of beta carotene supplementation for the prevention of cardiovascular disease or cancer outweigh the benefits.
- The USPSTF concludes with moderate certainty that there is no net benefit of supplementation with vitamin E for the prevention of cardiovascular disease or cancer.
- The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation with multivitamins for the prevention of cardiovascular disease or cancer.
- The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation
 with single or paired nutrients (other than beta carotene and vitamin E) for the prevention of cardiovascular disease or cancer.



Supplements for the Primary Prevention of Cardiovascular Disease and Cancer








For management of dyslipidemias, supplements are often used by patients in place of statins, in the absence of high-quality data.

Consumer research suggests most U.S. consumers <u>believe cholesterol health supplements are</u> <u>safer than prescription medications.</u>

Majority of the public also believe supplements are as effective, or more effective, than statins.






SPORT trial



Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers



Luke J. Laffin, MD,^a Dennis Bruemmer, MD,^a Michelle Garcia, RN,^b Danielle M. Brennan, MS,^b Ellen McErlean, MSN,^b Douglas S. Jacoby, MD,^c Erin D. Michos, MD,^d Paul M Ridker, MD,^e Tracy Y. Wang, MD,^f Karol E. Watson, MD,^a Howard G. Hutchinson, MD,^b Steven E. Nissen, MD^{a,b}



Compare the efficacy of a **low-dose statin** with placebo and **6 common supplements** in impacting lipid and inflammatory biomarkers








Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers



Luke J. Laffin, MD,^a Dennis Bruemmer, MD,^a Michelle Garcia, RN,^b Danielle M. Brennan, MS,^b Ellen McErlean, MSN,^b Douglas S. Jacoby, MD,^c Erin D. Michos, MD,^c Agul M Ridker, MD,^a Tracy Y. Wang, MD,^c Karol E. Watson, MD,^a Howard G. Hutchinson. MD,^b Steven E. Nissen. MD,^{ab}



Inclusion Criteria



- 40 and 75 years
- LDL-C of 70 to 189 mg/dL
- no history of atherosclerotic cardiovascular disease
- not taking statins or other prescription lipid-lowering therapy

Exclusion Criteria

- liver dysfunction
- fasting serum triglycerides >200 mg/dL.
- glomerular filtration rate of <30 mL/min/m2.



CARDIO SANTARÉM SUPPLEMENTATION ON DYSLIPIDEMIAS






Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and **Inflammatory Biomarkers**

Luke J. Laffin, MD, a Dennis Bruemmer, MD, a Michelle Garcia, RN, Danielle M. Brennan, MS, Ellen McErlean, MSN, D Douglas S. Jacoby, MD, Erin D. Michos, MD, Paul M Ridker, MD, Tracy Y. Wang, MD, Karol E. Watson, MD, E Howard G. Hutchinson, MD, h Steven E. Nissen, MDa,



Primary endpoint: LDL reduction after 28 days





o colesterol







Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers



Luke J. Laffin, MD, * Dennis Bruemmer, MD, * Michelle Garcia, RN, * Danielle M. Brennan, MS, * Ellen McErlean, MSN, * Douglas S. Jacoby, MD, * Erin D. Michos, MD, * Daul M Ridker, MD, * Tracy Y. Wang, MD, * Karol E. Watson, MD, * Leward C. Witchelbiscon, MD, * Estemp. The Street, MD, * Desperation of the Month of th

Rosuvastatin Decreased LDL-C, Total Cholesterol, and Serum Triglycerides Significantly More Than Placebo and Each Supplement

Total LDL-C Cholesterol

Cholesterol Triglycerides

HDL-C

hsCRP











No difference in LDL-C reduction with any supplement compared to placebo

Supplements marketed or promoted for "cholesterol health" do not significantly lower LDL-C compared with placebo



No difference in adverse effects

Patients should be educated about the lack of benefit of these supplements on important cardiovascular risk factors.



TAKE HOME MESSAGES

- ✓ Dietary **supplementation is a very common** practice in developed countries.
- ✓ <u>Disease prevention (cardiovascular disease and cancer</u>) are common reasons appointed for supplement intake.
- ✓ Multivitamins do not seem to be effective in CV disease.
- ✓ Supplementation may carry harms in specific patients (Beta carotene, Vit E)
- ✓ <u>Supplements promoted for "cholesterol health" do not significantly lower LDL-C</u> compared with placebo.



MITOS OU REALIDADES NA PREVENÇÃO CARDIOVASCULAR

SUPLEMENTOS NA SAÚDE E DOENÇA CARDIOVASCULAR

Bruno Miranda Castilho

Cardiologia – Hospital Distrital de Santarém